TRIM7 Inhibition Blocks RTK/RAS Pathway Driven Tumor Proliferation Independent of Mutation & in the Setting of KRASi Resistance
- KT-300 is a covalent small molecule inhibitor of the E3 ubiquitin ligase TRIM7, which is hyperactivated in RTK/RAS driven cancers, enabling broad activity across tumor types and offering a potential path beyond mutation-specific targeting strategies
- KT-300 is active in the setting of KRAS inhibitor resistance, and may support sustained pathway suppression and improve the potential for durable responses in RAS-driven cancers
- Combined blockade with KT-300 and upstream RAS-pathway inhibition (e.g.; anti- EGFR, KRASi, etc.) enhance anti-tumor responses, creating broad opportunities for rationale combinations